Individual Proton Pump Inhibitors and Outcomes in XXXX With @entity453 on Dual Antiplatelet Therapy: A Systematic Review.

@entity1 @entity1187 @entity64 @entity1537 @entity7371 @entity1397 @entity10042 @entity453 @entity10112 @entity583 @entity204 @entity4546
BACKGROUND: Observational studies evaluating the possible interaction between proton pump inhibitors (PPIs) and @entity1397 have shown mixed results. We conducted a systematic review comparing the safety of individual PPIs in @entity1 with @entity453 taking @entity1397 . METHODS AND RESULTS: Studies performed from January 1995 to December 2013 were screened for inclusion. Data were extracted, and study quality was graded for 34 potential studies. For those studies in which follow-up period, outcomes, and multivariable adjustment were comparable, meta-analysis was performed.The adjusted odds or hazard ratios for the composite of cardiovascular or all-cause @entity204 , @entity583 , and @entity64 at 1 year were reported in 6 observational studies with data on individual PPIs. Random-effects meta-analyses of the 6 studies revealed an increased risk for adverse cardiovascular events for those taking @entity10112 (hazard ratio 1.38; 95% CI 1.12-1.70), @entity10042 (hazard ratio 1.29; 95% CI 1.09-1.52), or @entity1537 (hazard ratio 1.27; 95% CI 1.02-1.58) compared with @entity1 on no PPI. This association was not significant for @entity4546 (hazard ratio 1.16; 95% CI 0.93-1.44). Sensitivity analyses for the @entity453 ( @entity1187 versus mixed) and exclusion of a single study due to heterogeneity of reported results did not have significant influence on the effect estimates for any PPIs. CONCLUSIONS: Several frequently used PPIs previously thought to be safe for concomitant use with @entity1397 were associated with greater risk of adverse cardiovascular events. Although the data are observational, they highlight the need for randomized controlled trials to evaluate the safety of concomitant @entity7371 and @entity1397 use in @entity1 with @entity453 .
